

March 1, 2022

Dear Lantheus Medical Imaging Customer,

After careful consideration, we have made the decision to discontinue production of Thallium-201 and Gallium-67 in late 2022. Given the continued decline in global demand, as well as the age of the infrastructure specific to these two products, supply of these products is no longer sustainable. We believe that there are adequate alternatives in the market, including other modalities, to avoid detrimental effect on patients. Further, we hope that the advance notice provided to you will allow time for you to work with your customers as necessary to adjust.

Please note that this correspondence is intended to provide any notice which may be required under your agreement with Lantheus.

Our commitment to the nuclear medicine community remains strong with continued supply and support of our other SPECT products, including Technelite®, Xenon-133, Neurolite®, Cardiolite®, and sestamibi. Should you have any questions, or need additional information, please contact your Lantheus Nuclear Medicine Account Director, or Lantheus Customer Service at 1-800-299-3431.

Sincerely,

John Wiggins

Vice President, Head of Global SPECT Franchise